Comparison
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 vs 16p13 11 Microduplication Syndrome C4304595
Clinical comparison between 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia and 16p13 11 Microduplication Syndrome for differential diagnosis and treatment planning.
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
An inherited disorder affecting adrenal hormone production, causing cortisol deficiency and other hormonal imbalances. Features may include ambiguous genitalia, salt-wasting crises, and growth issues. Treated with lifelong hormone replacement therapy.
16p13 11 Microduplication Syndrome C4304595
A rare genetic condition from duplication of a segment on chromosome 16. Features may include developmental delays and learning differences. Management focuses on supportive care and early intervention.
6 comparison axes
Onset
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
0-null
16p13 11 Microduplication Syndrome C4304595
0-null
Onset patterns differ
Severity
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
severe
16p13 11 Microduplication Syndrome C4304595
moderate
Different severity levels
Chronic
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
Chronic
16p13 11 Microduplication Syndrome C4304595
Chronic
Differing course
Communicable
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
No
16p13 11 Microduplication Syndrome C4304595
No
Different transmission
Body System
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
endocrine
16p13 11 Microduplication Syndrome C4304595
congenital
Same/different system
Category
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
endocrine
16p13 11 Microduplication Syndrome C4304595
genetic
Different category
Bottom line
21-hydroxylase-deficient-congenital-adrenal-hyperplasia-C2936858 and 16p13-11-microduplication-syndrome-C4304595 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 | 16p13 11 Microduplication Syndrome C4304595 | Discriminating power |
|---|---|---|---|
| Genital or sex-development findings | May include atypical genitalia or androgen excess, depending on sex and severity. | Not a characteristic endocrine genital phenotype in available descriptions. | High |
| Acute salt-wasting illness | Severe forms may cause salt-wasting crisis with dehydration and electrolyte imbalance. | Not described as causing adrenal salt-wasting crises. | High |
| Developmental or learning differences | Not the primary defining feature; growth may be affected. | May include developmental delay and learning differences, with variable expression. | Moderate |
When to favor each condition
Choose 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 when
Newborn with atypical genitalia or suspected adrenal crisis
Endocrine evaluation is urgent because cortisol deficiency and salt wasting can be life-threatening.
High
Abnormal newborn screening suggesting CAH
A screening result is not a diagnosis and needs confirmatory endocrine and genetic assessment.
High
Family history of 21-hydroxylase deficiency
Targeted genetic and endocrine testing can clarify carrier or affected status.
Moderate
Choose 16p13 11 Microduplication Syndrome C4304595 when
Developmental delay with a chromosomal microarray finding
A reported 16p13.11 duplication should be interpreted by genetics in clinical context.
High
Learning differences without adrenal symptoms
This pattern fits the described neurodevelopmental condition better than CAH.
Moderate
Family variant of uncertain or variable effect
Penetrance and phenotype may vary, so clinician correlation is required.
Moderate
How key tests differ
| Test | 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 | 16p13 11 Microduplication Syndrome C4304595 | Interpretation |
|---|---|---|---|
| Adrenal steroid profile | May show cortisol deficiency and androgen excess; exact cutoffs are not stated here. | No characteristic adrenal steroid abnormality is established. | Abnormal steroids support CAH evaluation but require laboratory confirmation. |
| CYP21A2 genetic testing | Pathogenic variants can confirm 21-hydroxylase deficiency. | Not the diagnostic test for a chromosome 16 duplication. | Gene testing addresses CAH, not the microduplication. |
| Chromosomal microarray | Not expected to diagnose 21-hydroxylase deficiency. | May detect a 16p13.11 copy-number gain. | A copy-number finding needs genetics review and is not itself a complete clinical diagnosis. |
Prognosis comparison
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
- Outcome
- Often a lifelong endocrine condition; outcome depends on severity and treatment response, which are not quantified here.
- Factors
- Salt-wasting status, hormone control, illness management, and access to specialist care.
16p13 11 Microduplication Syndrome C4304595
- Outcome
- Variable and not fully predictable from the duplication alone.
- Factors
- Developmental profile, associated findings, family phenotype, and support services.
Time frame: Both can be chronic; exact long-term outcomes are not established in the supplied data.
Diagnosis confirmation, comorbidities, and individualized follow-up influence outlook.
Complications comparison
| Complication | Presentation |
|---|---|
| Adrenal crisis | Possible in severe cortisol-deficient disease, especially with illness or stress. Not an established feature. Suspected crisis needs emergency care; this comparison does not provide treatment doses. |
| Growth and puberty effects | Hormonal imbalance may affect growth and pubertal development. Growth effects are not established from the supplied description. Endocrine follow-up is appropriate when CAH is confirmed or suspected. |
| Neurodevelopmental needs | Not the core complication described. Developmental delay and learning differences may require ongoing support. Needs vary; early developmental assessment is reasonable. |
Patient education highlights
- HighDifferent causes
CAH affects adrenal hormones, while 16p13.11 microduplication is a chromosomal finding with variable developmental effects.
- HighUrgent symptoms
Vomiting, lethargy, dehydration, or collapse in suspected CAH needs urgent medical assessment.
- MediumSupportive care
Microduplication management is individualized and may include developmental and educational support.